Managing Director Jason Wittes of Brean Capital says Globus Medical Inc (GMED) is in a strong position right now. He says the company is a $2 billion-plus market cap name that is well-capitalized and able to service markets as effectively as J&J or Medtronic.
“But they still have that focus and, most would argue, a significantly better product portfolio offering than those two largest players,” he says. “They’re unique in having the right scale and focus.”
That, Wittes says, is why Globus is consistently growing its top line in the low double digits. He anticipates that the company can continually drive strong topline growth, given its current position.
“Globus already has best-in-class operating margins, but I see opportunity for accelerated growth as it expands into trauma — an area where its aggressive product development and sales strategy could prove even more successful than it was in spine, given it’s a less competitive space,” Wittes says.
Trauma Surgery Director Turned Equity Analyst Picks Medtech Stock Winners
June 09, 2023
Proofpoint Inc (PFPT) Has Significant Growth Opportunity in Advanced Threat Protection Market
September 26, 2014
LinkedIn Corp (LNKD) Has Upside Opportunity for Sales Navigator Business, Grows EBITDA at 60% CAGR
May 21, 2013
Laboratory Corp. of America Holdings (LH) Has Revenue-Synergy Opportunity from Covance Acquisition
May 13, 2015
American Tower Corp (AMT) Has Tremendous Global Opportunity
October 21, 2015
